Login / Signup

The Effect of Bifidobacterium animalis subsp. lactis Bl-04 on Influenza A Virus Infection in Mice.

Bryan ZabelSanna M MäkeläDerek NedveckAshley A HibberdNicolas YeungSinikka LatvalaLiisa LehtorantaJouni J T JunnilaKevin B WaltersWesley MorovicMarkus J Lehtinen
Published in: Microorganisms (2023)
Influenza A virus infection is a major global disease requiring annual vaccination. Clinical studies indicate that certain probiotics may support immune function against influenza and other respiratory viruses, but direct molecular evidence is scarce. Here, mice were treated with a placebo or Bifidobacterium animalis subsp. lactis Bl-04 (Bl-04) orally via food (cereal) and also by gavage and exposed to Influenza A virus H1N1 (H1N1). The symptoms of the infection were observed, and tissues and digesta were collected for viral load RT-qPCR, transcriptomics, and microbiomics. The treatment decreased the viral load by 48% at day 3 post-infection in lungs and symptoms of infection at day 4 compared to placebo. Tissue transcriptomics showed differences between the Bl-04 and placebo groups in the genes in the Influenza A pathway in the intestine, blood, and lungs prior to and post-infection, but the results were inconclusive. Moreover, 16S rRNA gene profiling and qPCR showed the presence of Bl-04 in the intestine, but without major shifts in the microbiome. In conclusion, Bl-04 treatment may influence the host response against H1N1 in a murine challenge model; however, further studies are required to elucidate the mechanism of action.
Keyphrases
  • single cell
  • genome wide
  • double blind
  • randomized controlled trial
  • clinical trial
  • metabolic syndrome
  • sleep quality
  • phase iii
  • risk assessment
  • insulin resistance
  • transcription factor
  • placebo controlled
  • human health